Neuroendocrine Tumours: A Retrospective Analysis in a Single Irish Institution Abstract #1576

Introduction: Neuroendocrine tumours(NETs)are heterogenous group of tumours.
Aim(s): We conducted a retrospective analysis in a tertiary centre to evaluate these patients’ clinicalhistopathological characteristics, treatments and outcomes.
Materials and methods: All non-metastatic and metastatic NETs (all grades and sites) diagnosed from April 2011 to May 2015 were included. Small-cell lung neuroendocrine carcinomas were excluded.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: DR Cha Len Lee
Keywords: neuroendocrine

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2250 Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)
Introduction: Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) have been newly defined in the WHO 2017 classification. They are rare tumors, commonly treated in analogy to their non-neuroendocrine (nNE) or neuroendocrine (NE) component without systematic data regarding the optimal therapeutic strategy.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis
#1761 Incidentally Detected Pancreatic Neuroendocrine Microadenoma with Lymph Node Metastasis
Introduction: Pancreatic neuroendocrine microadenomas are tumor with <0.5 cm size and considered as benign.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: MD, PhD Seung-Mo Hong
Authors: Hong S M, Kwon J H, Kim H J, Lee Y J, ...
#1773 Clinical Outcomes of Systemic Chemotherapy in Patients with High Grade Neuroendocrine Carcinoma of Biliary Tract
Introduction: : Neuroendocarine tumor of biliary tract is very rare and clinical outcomes of advanced neuroendocrine tumors of biliary tract has not been well demonstrated.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: MD Changhoon Yoo
Authors: Yoo C, Lee K, Kim K P, Chang H M, ...
#1752 Neuroendocrine Tumors: A Retrospective Analysis in a Single Algerien Institution
Introduction: Neuroendocrine tumors (NETs) are heteregenous group of tumors.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: ...none of the above
Presenting Author: doctor Belabdi Djihed
Authors: Djihed B, Alyda M, Mohammed O, ...
#3033 First-in-Korea Clinical Trial of Lu-177-DOTATATE in Patients with Inoperable, Progressive Somatostatin Receptor-Positive, Metastatic or Locally Advanced Neuroendocrine Tumor (SNU-KB-01)
Introduction: Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Minseok Suh
Authors: Suh M, Cheon G J, Lee D S, ...